|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| A comparative study of monophasic oral contraceptives containing either |
| drospirenone 3 micrograms or levonorgestrel 150 micrograms on premenstrual |
| Sangthawan M; Taneepanichskul S |
| Contraception. 2005;71:1-7. |
| This open-label randomized study compared the effects of two combined oral contraceptives (OCs) containing 3 mg |
| drospirenone (DRSP)/30 µg ethinyl estradiol (EE) with 150 µg levonorgestrel (LNG)/30 µg EE on the prevalence and |
| changes from baseline of premenstrual symptoms after six cycles. The symptoms were measured using the |
| Women's Health Assessment Questionnaire. Subjects receiving DRSP/EE had fewer prevalence of premenstrual |
| symptoms than those receiving LNG/EE after six cycles. A significantly lower score of negative affect category in the |
| premenstrual phase was demonstrated in those receiving DRSP/EE more than LNG/EE. The DRSP/ EE group |
| showed a greater improvement of mean scores from baseline in the premenstrual phase compared with those who |
| received LNG/ EE on negative affect as seen in the items on anxiety, irritability, feeling sad or blue and weight gain in |
| the category of water retention. In conclusion, OCs containing DRSP have beneficial effects in reducing the |
| prevalence of premenstrual symptoms especially the symptoms of negative affect and weight gain, particularly when |
| compared to LNG/EE. Hence, it should be recommended for women who are susceptible to these adverse |
| symptoms. (PubHealth.info Document ID: CONT1T 87-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "A comparative study of monophasic oral contraceptives |
| containing either drospirenone 3 micrograms or levonorgestrel 150 micrograms on premenstrual symptoms.", is(are) |
| Sangthawan M; Taneepanichskul S. The source of this article is "Contraception. 2005;71:1-7.". This article was |
| published in 2005 in English language(s). (PubHealth.info® Document ID: CONT1T 87-06. All rights reserved with |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |